Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro January 11, 2026
Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next-Gen Bispecific ADCs January 11, 2026
STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications January 11, 2026
DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies January 11, 2026
Parabilis Medicines Announces Oversubscribed $305 Million Financing to Support Ongoing FOG-001 (zolucatetide) Clinical Development January 11, 2026
Pierre Fabre Laboratories and Iktos announce Integrated Drug Discovery Collaboration January 11, 2026
Ph 3 KANDLELIT-007 Trial of Calderasib (MK-1084) + KEYTRUDA QLEX Initiated in Certain Patients With Advanced NSCLC January 11, 2026
Clinical Update provided on Ph 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety and Efficacy Data Observed in a Patient with MDS/AML January 11, 2026
Promising Data from Ongoing Ph 2a study for BI-1808 with KEYTRUDA in Recurrent Ovarian Cancer Reported January 11, 2026
Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials Reported January 11, 2026
Data from Ph 1/2 trial of Multi-Antigen Targeted T cells in patients with pancreatic cancer announced January 11, 2026
BRAFTOVI® Regimen with Additional Chemo Backbone Increased Response Rates for Certain Patients with Metastatic CRC January 11, 2026
Positive ACR-368 Ph 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840 Data Announces January 11, 2026
VYLOY™ (zolbetuximab) + Chemo Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses January 11, 2026
Strong Topline Ph 2 Results for DSP107 in Combination with Anti-PD-L1 Therapy in CRC Announced January 11, 2026
Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) in 1L DLBCL Announced January 11, 2026
Ziihera (zanidatamab-hrii) Results in 1L HER2+ Locally Advanced or Metastatic GEA Announced Including 2+ Years Median OS Benefit January 11, 2026
64% OS At 12 Months Announced in 1L Pancreatic Cancer Patients Treated with Atebimetinib + mGnP January 11, 2026
Regulatory Clearances of IND Applications for CR-001 & CR-003 for the Treatment of Solid Tumors Announced January 11, 2026
